If you want to find buyers then take it down to $1.50 & I'll pick up a few shares.
Investors have probably figured out what's going on now & refuse to throw good money after bad.
Sliky, I'm not sure that's true. I think they shorted the stock from $3 so their cost basis for those shares may be $1.50.
The markets not in a buying mood at any price.
First time I've seen you hedge your bet. If I'm right then all is good & if I'm wrong I can afford the loss.
Price targets are based on the company achieving certain goals. A bunch of guess work goes into the estimates.
How accurate have you been with your number crunching?
Maybe they're trying to push the shareprice down low enough so that someone may think ATRS is an attractive acquisition target. If someone offered $3.50 for ATRS at this point then I doubt you would hear anything but a sigh of relief from investors.
I know he was touting how smart Deerfield was for buying the secondary. Is Deerfield also smart for selling?
I have no problem giving them the same rights as traditional marriages.
They only have data on 3 patients & all of them showed a significant reduction in itching. I realize the individual on the highest dose initially showed increased itching on day 1 but then it steadily decreased. I think the data's good
I think its going to be difficult to get a good sense of the efficacy, reduction in side effects, & market opportunities from CARA's & TRVN's current trials. I sold out of CARA but the smartest thing maybe to just have a position in both companies. I'm going to buy back a few shares. Both of the companies have a long way to go but they're still cheap & could explode on decent data.
Namm, the FDA has listed a drug supply shortage for Epi since 2012. If ATRS investors want to act like its going to impact sales or speed up the approval then go right ahead.